Keith L. Brownlie
Mr. Brownlie has been a director of Celldex since June 2017. He was employed by the accounting firm Ernst & Young LLP from 1974 to 2010, where he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York metropolitan area. He currently serves as a member of the boards of directors and chairman of the audit committees for two publicly-held biopharmaceutical companies—Soligenix, Inc. and RXi Pharmaceuticals Corporation, and he previously served in the same capacity for the publicly-held EpiCept Corporation and Cancer Genetics, Inc. Mr. Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant.